BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33648463)

  • 1. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
    Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
    BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course.
    Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
    Oncotarget; 2020 Aug; 11(33):3153-3173. PubMed ID: 32913559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.
    Balsas P; Veloza L; Clot G; Sureda-Gómez M; Rodríguez ML; Masaoutis C; Frigola G; Navarro A; Beà S; Nadeu F; Giné E; López-Guillermo A; Martínez A; Ribera-Cortada I; Engel P; Quintanilla-Martínez L; Klapper W; Campo E; Amador V
    Blood; 2021 Dec; 138(22):2202-2215. PubMed ID: 34189576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
    Castillejo A; Rothman N; Murta-Nascimento C; Malats N; García-Closas M; Gómez-Martínez A; Lloreta J; Tardón A; Serra C; García-Closas R; Chanock S; Silverman DT; Dosemeci M; Kogevinas M; Carrato A; Soto JL; Real FX
    Int J Cancer; 2009 Feb; 124(3):608-13. PubMed ID: 19004027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma.
    He JX; Xi YF; Su LP; Gao N; Xu EW; Xie LW; Wang LY; Zheng YP; Han WE; Chang J; Wang HW
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2556-2563. PubMed ID: 29771407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
    Nylund P; Nikkarinen A; Ek S; Glimelius I
    Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
    Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
    Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
    Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.
    Nygren L; Baumgartner Wennerholm S; Klimkowska M; Christensson B; Kimby E; Sander B
    Blood; 2012 May; 119(18):4215-23. PubMed ID: 22431568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
    Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
    Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-nucleotide variants in TGFB1, TGFBR2, IL17A, and IL17F immune response genes contribute to follicular lymphoma susceptibility and aggressiveness.
    Assis-Mendonça GR; Lourenço GJ; Delamain MT; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
    Blood Cancer J; 2020 Oct; 10(10):97. PubMed ID: 33024088
    [No Abstract]   [Full Text] [Related]  

  • 18. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.
    Wang X; Björklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B
    PLoS One; 2010 Nov; 5(11):e14085. PubMed ID: 21124928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.